Quality/GMPs

The FDA is encouraging manufacturers to invest in research and development for new vaccines and therapeutics to combat third-world diseases.

ICH Q9 encourages companies to apply the concept of quality risk management. Easier said than done.

A better method for trend analysis than CUSUM and control charts.

Select the best approach to determine critical quality attributes.

Perhaps the best way to regulate drugs is to regulate them not conservatively or liberally, but effectively.

A case study in capturing indirect costs and benefits.

Enabling site-wide process efficiency.

Pressures to reduce healthcare spending generates proposals to spur competition, cut costs.

Companies often wait for a critical mass before adopting new technologies. But if no one takes the risk, critical mass will never be reached.

A culture of quality that emphasizes business objectives, risk management, and the informed application of technology can improve compliance.

The introduction of two rival bills has intensified the long-simmering debate on biosimilars regulation in the US.

The truth is, we should have been afraid of H1N1, because the threat of a flu pandemic is real.

Biopharmaceutical companies must follow an active approach to managing their supply chains.

The FDA seeks new strategies for improving the safe use of opioids and other high-risk medicines, including erythropoiesis stimulating agents.

Agency officials promise swift action against violators of drug safety and quality regulations.

Importing foreign drugs is not the best way to increase access to medicine. The risks are too high, and it burdens the over-stretched FDA unfairly.

How to maintain product stability and prevent particulates.

New expression systems compete for attention.

Use Lean techniques to improve manufacturing compliance

Without a rigorous discussion of the pros and cons of QbD, its tremendous benefits will be lost.

How to optimize facility utilization and improve plant performance.

Avoiding healthcare reform is not the best option for the pharmaceutical industry.

Why the industry needs to review its traditional approach to facility validation

This article reviews some of the commonly used approaches for process monitoring as well as the evolution of process monitoring in the Quality by Design (QbD) paradigm.

Authorities are pushing for CE; manufacturers prefer to focus on value.